TITLE:
Hyperhomocysteinemia and Associated Biological Markers in a Congolese Population of Type 2 Diabetes Mellitus in Brazzaville
AUTHORS:
V. R. Ikia Monde, A. L. M. Boumba, E. Mokondjimobe, H. Poaty, G. Loubano-Voumbi, W. F. Ondongo, A. G. Mayindou Kimbangu, K. Onanga, F. Elilie Mawa Ongoth, E. Bouenizabila, C. Andres, H. G. Monabeka
KEYWORDS:
Hyperhomocysteinemia, Biological Markers, T2DM, Brazzaville
JOURNAL NAME:
Open Journal of Endocrine and Metabolic Diseases,
Vol.14 No.6,
June
28,
2024
ABSTRACT: The search for new biomarkers predictive of type 2 diabetes currently constitutes a research avenue in Bioclinical. Total homocysteine remains a preferred target due to its involvement in the occurrence of degenerative complications in type 2 diabetics. The aim of this work was to study hyperhomocysteinemia and other biochemical markers associated with T2D in the Congolese population. This was an analytical case-control study carried out between October 2022 and October 2023. The study population consisted of 150 subjects including 100 T2D patients and 50 control subjects. The main clinical data were collected on a pre-established form. Homocysteine determination was carried out by the sandwich ELISA method. The other biochemical markers were measured by colorimetric enzymatic methods. Hyperhomocysteinemia was present in 27.3% (41/150) of the entire study population. Type 2 diabetics had a frequency of hyperhomocysteinemia of 36% (36/100) and control 10% (5/50) (p = 0.001). The mean hyperhomocysteinemia concentration was 31.9 μmol/l with extremes ranging from 18 to 103 μmol/l. Means of biological markers between diabetics and controls showed a statistically significant difference (p = 0.01). The risk factors associated with this HHcy were: sex (OR = 3.5), age (OR = 9.4), sedentary lifestyle (OR = 3.4) and glycosylated hemoglobin (OR = 12) with a p-value